查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924500

尿石素B市场按用途、形态、来源、通路、最终用户和等级划分－2026-2032年全球预测

Urolithin B Market by Application, Form, Source, Distribution Channel, End User, Grade - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年尿石素 B 市值为 7.7822 亿美元，预计到 2026 年将成长至 8.5441 亿美元，预计到 2032 年将达到 16.0369 亿美元，复合年增长率为 10.88%。

关键市场统计数据
基准年 2025 7.7822亿美元
预计年份：2026年 8.5441亿美元
预测年份 2032 1,603,690,000 美元
复合年增长率 (%) 10.88%

对尿石素B的科学起源、生产途径和商业化策略考量进行了简明扼要且权威全面的说明

尿石素B的出现源自于肠道微生物组科学与功能性成分创新的融合，它已成为配方师、临床医生和原料生产商极为关注的生物活性化合物。该化合物由肠道微生物代谢膳食来源的鞣花单宁在体内产生，也可透过可控制生物发酵或合成途径取得。尿石素B因其支持粒线体功能、抗发炎活性和增强肌肉性能等潜在特性而备受瞩目。分析化学的进步、可重复的生产技术以及不断扩展的转化研究，已使尿石素B从实验室中的奇特化合物发展成为具有多种潜在商业应用的领先候选药物。

技术成熟度、监管审查和不断变化的消费者偏好如何共同作用，重塑尿石素B商业化的机会和障碍

受技术、监管和消费者主导等多面向因素的影响，尿石素B的市场格局正在快速变化，其商业化路径也随之重塑。精准生物发酵技术的进步降低了产品变异性，并提高了产量稳定性，使供应商能够提供杂质谱更窄、功能效果更可预测的产品。同时，合成化学的进步正在创造可扩展的替代方案，以满足生物来源原料供应紧张情况下的需求，从而支持供应多元化和单位成本优化。

评估2025年美国关税变化对尿石素B供应链韧性、筹资策略和在地化生产的策略影响

2025年新关税的实施为尿石素B相关相关人员带来了复杂的供应链、采购和定价挑战。由于这种生物活性物质的生产过程可能依赖进口前体、专用发酵设备或契约製造关係，进口关税的分阶段实施将直接影响最终到岸成本以及国内与海外生产决策。为此，一些供应商正在加快对本地生物发酵能力和分析实验室的投资，以降低跨境价格波动风险。

策略性細項分析能够深入洞察用途、剂型、来源、通路、最终用户和等级选择如何决定配方开发路径和商业化策略。

细分市场层面的趋势能够最有效地洞察尿石素B在相关产业和产品结构中的应用前景。应用细分决定了配方和监管方面的优先事项：在化妆品和个人护理领域，稳定性、局部安全性和与现有载体系统的相容性是关键需求；在营养保健品领域，口服生物有效性以及易于包封和压片至关重要；在机能性食品和饮料领域，必须考虑掩味、溶解性和热稳定性；在製药领域，最高纯度和可控的临床路径必不可少和可控的临床路径。

区域战略考量：美洲、欧洲、中东和非洲以及亚太地区的趋势将如何影响生产、研发重点和商业化优先事项。

区域趋势将决定在生产、临床研究和商业性伙伴关係的投资在哪些地区能够获得最大回报。在美洲，对经临床验证的营养保健品和功能性成分的需求正推动着运动营养品和膳食补充剂生产商的浓厚兴趣。这得益于当地强大的临床研究文化以及消费者愿意为差异化的生物活性成分买单。这种环境促使供应商优先进行人体干预研究，并优化符合消费者习惯的产品形式，例如胶囊和粉末。

构成尿石素B生态系统的原料开发商、契约製造和商业伙伴的企业策略和竞争策略

尿石素B价值链上的企业正采取多种策略来确保竞争优势，从专有的培养技术平台到整合临床数据和分销能力的合作关係，不一而足。创新者正投资于上游工程开发，以降低变异性，透过一致的杂质谱实现差异化，并提高稳定性。作为回应，契约製造製造商和原材料供应商正在扩展其分析能力，以提供符合化妆品、食品和药品标准的多种等级的认证批次产品。

为确保尿石素B的供应稳定、获得监管机构批准和市场差异化，製造商、配方师和商业团队可采取切实可行的优先行动。

我们鼓励业界领导者采取多元化、风险管理的策略，以掌握尿石素B带来的机会。首先，应优先投资于品质和原料可追溯性，具体措施包括扩展分析基础设施，并对生物发酵和合成来源合格。这将确保业务永续营运，并支持针对不同等级尿石素B的扩张。这种方法将减少对单一来源的依赖，并支援根据客户需求的变化，在化妆品、食品、药品和标准等级之间快速切换。

一种透明、多方面的调查方法，结合了深度访谈、实验室检验、监管分析和供应链分析，为策略建议提供支援。

为确保研究结果的稳健性和相关性，本研究采用了多种互补的方法。一级资讯来源包括对原料研发人员、契约製造、法规顾问和製剂研发人员的结构化访谈，以了解他们的实践和商业性意图。二级资讯来源包括对同侪审查文献、临床试验註册库、专利申请和监管公告的系统性回顾，以检验作用机制、安全性概况和申报资料要求。这些资讯来源的整合使我们能够从多层次理解科学检验、智慧财产权趋势和合规标准。

成功扩大尿石素B解决方案规模的关键在于科学、製造和商业性要素的整合。

尿石素B正处于科学检验、生产成熟度和商业性需求交会的关键节点，由此衍生出多种价值创造路径。该成分的未来将取决于相关人员能否证明其具有可重复的生物学效应，能否确保建立稳健且分级的供应链，以及能否使产品形态和功效宣称与特定管道的预期相符。随着证据基础的不断扩展和生产方式的增多，那些能够平衡临床投入、营运严谨性和本地市场敏感性的公司，将更有能力将潜力转化为持续的商业性成功。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依应用分類的尿石素B市场

  • 化妆品和个人护理
  • 营养补充品
  • 机能性食品和饮料
  • 製药

9. 尿石素B市场依形式划分

  • 胶囊
  • 液体
  • 粉末
  • 药片

第十章 尿石素B市场（依来源划分）

  • 生物发酵
  • 合成

第十一章 尿石素B市场（依分销管道划分）

  • 直销
  • 在线的
  • 专卖店

第十二章 尿石素B市场（依最终用户划分）

  • 化妆品製造商
  • 营养补充品製造商
  • 製药公司
  • 研究所

第十三章 尿石素B 市场依等级划分

  • 化妆品级
  • 食品级
  • 医药级
  • 标准级

第十四章 各地区尿石素B市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 尿石素B市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国尿石素B市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国尿石素B市场

第十八章 中国尿石素B市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bio-Botanica Inc.
  • Cayman Chemical Company
  • Hangzhou Ark Biotechnology Co., Ltd.
  • Indena SpA
  • International Flavors & Fragrances Inc.
  • Merck KGaA
  • Nutraveris SAS
  • PLT Health Solutions Ltd.
  • Sabinsa Corporation
  • Toronto Research Chemicals Inc.
Product Code: MRR-7A380DA7C358

The Urolithin B Market was valued at USD 778.22 million in 2025 and is projected to grow to USD 854.41 million in 2026, with a CAGR of 10.88%, reaching USD 1,603.69 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 778.22 million
Estimated Year [2026] USD 854.41 million
Forecast Year [2032] USD 1,603.69 million
CAGR (%) 10.88%

A concise, authoritative synthesis of Urolithin B's scientific origins, manufacturing pathways, and strategic considerations for commercial translation

Urolithin B has emerged from the confluence of gut microbiome science and functional ingredient innovation to become a high-interest bioactive for formulators, clinicians, and ingredient manufacturers. Derived in vivo from dietary ellagitannins through microbial metabolism and available via controlled biofermentation or synthetic routes, this compound has attracted attention for its putative mitochondrial-supportive, anti-inflammatory, and muscle-performance properties. The convergence of improved analytical chemistry, reproducible manufacturing techniques, and an expanding body of translational research has moved Urolithin B from laboratory curiosity into a credible candidate for multiple commercial applications.

In practice, the development pathway for Urolithin B demands a multidisciplinary approach that balances rigorous clinical evidence, regulatory navigation, and manufacturing quality. Regulatory clarity and grade differentiation shape how the ingredient can be deployed across cosmetic, food, and pharmaceutical contexts, while advances in formulation science enable incorporation into capsules, liquids, powders, and tablets with predictable stability and bioavailability profiles. Given these dynamics, stakeholders-ranging from ingredient innovators and contract manufacturers to R&D teams within consumer brands-need a precise synthesis of scientific provenance, supply chain realities, and commercial use cases to prioritize investments and mitigate downstream risk.

Taken together, the introduction of Urolithin B into product pipelines reflects a broader shift in how novel bioactives are validated and commercialized: emphasis on mechanism-backed claims, scalable and reproducible supply, and segmentation-specific grade control to meet regulatory and safety standards. For strategic decision-makers, understanding these foundational elements is the precursor to building differentiated products that satisfy both regulatory scrutiny and consumer expectations.

How technological maturation, regulatory scrutiny, and evolving consumer preferences are converging to reshape opportunities and barriers for Urolithin B commercialization

The landscape for Urolithin B is shifting rapidly under the influence of technological, regulatory, and consumer-driven forces that are reshaping commercialization pathways. Advances in precision biofermentation have reduced variability and increased yield consistency, enabling suppliers to offer product forms with narrower impurity profiles and more predictable functional outcomes. At the same time, improvements in synthetic chemistry have produced scalable alternatives that can meet demand when biological feedstocks are constrained, supporting diversification of supply and unit-cost optimization.

Regulatory trajectories are also evolving; authorities are increasingly scrutinizing provenance, impurity profiles, and clinical substantiation for novel bioactives. This scrutiny is prompting companies to invest in robust toxicology packages and human intervention studies that can support differentiated claims for specific use cases. Concurrently, consumers are shifting their preferences toward scientifically substantiated, transparent ingredients and away from generalized wellness assertions. This trend encourages brands to prioritize clinical endpoints and to partner with research institutions to build credibility.

On the commercialization front, distribution and engagement models are transforming. Direct-to-consumer pathways and enhanced online specialty channels allow targeted product launches and rapid consumer feedback loops, while traditional contract sales and specialty retail remain important for institutional buyers and professional channels. Formulation advances-particularly for oral delivery systems-support the creation of multiple product types, expanding route-to-market options. These cumulative shifts underscore that success in the Urolithin B ecosystem requires simultaneous investments in manufacturing fidelity, clinical evidence, regulatory strategy, and channel-specific go-to-market planning.

Assessing the strategic consequences of the 2025 United States tariff changes on supply chain resilience, sourcing strategies, and manufacturing localization for Urolithin B

The implementation of new tariffs in 2025 has introduced a complex layer of supply chain, sourcing, and pricing considerations for stakeholders involved with Urolithin B. Because manufacturing pathways for this bioactive can rely on imported precursors, specialized fermentation equipment, or contract manufacturing relationships, incremental import duties have immediate implications for landed cost and for decisions about domestic versus offshore production. In response, some suppliers have accelerated investments in local biofermentation capacity and analytical laboratories to reduce exposure to cross-border volatility.

Moreover, tariffs have influenced procurement strategies across the value chain. Ingredient buyers in formulations have begun negotiating longer-term supply agreements and exploring dual-sourcing strategies that combine biofermented and synthetic options to preserve continuity if one pathway becomes economically disadvantaged. This rebalancing has ripple effects: contract manufacturers are reviewing master production schedules, cosmetic and supplement companies are re-evaluating price positioning, and specialty distributors are adjusting inventory holdings to manage margin compression.

At the same time, tariffs have incentivized certain firms to pursue greater vertical integration, absorbing portions of the upstream supply chain to capture margin and ensure quality controls. Importantly, these adjustments have not only economic consequences but also strategic ones: tighter control over manufacturing enables faster responses to regulatory requests for batch-level traceability and supports the generation of pharma-grade dossiers where needed. Looking forward, the cumulative impact of tariffs will likely remain a durable factor influencing capital allocation, partnership models, and the geographic distribution of production facilities across the broader Urolithin B ecosystem.

Strategic segmentation insights detailing how application, form, source, distribution channel, end-user, and grade choices determine formulation pathways and commercialization strategies

Segment-level dynamics provide the most actionable view of how Urolithin B will be adopted across adjacent industries and product architectures. Application segmentation drives formulation and regulatory priorities: in cosmetics and personal care contexts, demand centers on stability, topical safety, and compatibility with existing carrier systems; within dietary supplements, oral bioavailability and straightforward encapsulation or tableting are paramount; functional foods and beverages require taste-masking, solubility, and thermal stability considerations; and pharmaceutical uses necessitate the highest purity and controlled clinical development pathways.

Form considerations directly affect manufacturing and go-to-market choices. Capsule, liquid, powder, and tablet presentations each impose different constraints on excipients, stability testing, and packaging systems. For example, powders may be preferred where blend uniformity and controlled dosing are priorities, while liquids can accelerate direct-to-consumer product launches but demand preservative and stability strategies. The source of the ingredient-whether biofermented or synthetic-further shapes positioning, with biofermented supply often carrying consumer-facing narratives about natural origin and microbiome relevance, while synthetic routes can offer cost consistency and scalable supply that suits industrial-scale pharmaceutical or bulk supplement production.

Distribution channel segmentation influences commercialization cadence and customer engagement models. Direct sales and specialty store placements typically require deeper technical support and longer lead times to establish relationships with cosmetic manufacturers, dietary supplement manufacturers, and pharmaceutical companies. Conversely, online channels can accelerate consumer adoption but necessitate clear claims and robust quality assurances to withstand regulatory and consumer scrutiny. End-user segmentation also highlights divergent buyer needs: cosmetic manufacturers prioritize formulation compatibility and cosmetic grade specifications, dietary supplement manufacturers seek food grade or standard grade material with supply continuity, pharmaceutical companies demand pharmaceutical grade sourcing and full regulatory documentation, and research institutions often require small-batch, high-purity material for mechanistic studies.

Finally, grade differentiation-cosmetic grade, food grade, pharmaceutical grade, and standard grade-serves as a critical gating factor for pricing, certification, and allowable claims. Manufacturers and brands must align grade selection with intended use cases, regulatory pathways, and target channels to avoid product redeployment risks and to optimize time-to-market for each segment.

Regional strategic considerations explaining how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence production, research focus, and commercialization priorities

Regional dynamics will determine where investments in production, clinical research, and commercial partnerships yield the greatest return. In the Americas, demand for clinically substantiated nutraceuticals and performance ingredients drives interest from sports nutrition and dietary supplement manufacturers, supported by a strong culture of clinical research and consumer willingness to pay for differentiated bioactives. This environment encourages suppliers to prioritize human intervention studies and to optimize forms that align with consumer habits, such as capsules and powders.

Europe, Middle East & Africa exhibits a fragmented regulatory landscape and divergent consumer expectations that together shape entry strategies. Certain European markets emphasize natural origin and sustainability credentials, favoring biofermented supply chains and transparent sourcing narratives, while regulatory rigor in several jurisdictions requires substantive safety dossiers for novel ingredients. Middle Eastern and African markets are uneven in regulatory development but present channels for premium cosmetic deployments and specialty formulations, particularly when supported by localized partnerships and certification frameworks.

Asia-Pacific continues to be a dual-engine region: it hosts significant manufacturing scale and a vibrant R&D ecosystem capable of advancing both biofermentation and synthetic production routes, while burgeoning consumer demand for beauty-from-within and performance wellness products fuels commercial adoption. Cross-border trade, regional manufacturing clusters, and cost-competitive production make Asia-Pacific a strategically important place for both pilot manufacturing and larger-scale supply. Across regions, alignment between supply source, grade, and local regulatory expectations will determine the speed and scope of market entry, and companies that tailor their approach regionally will better mitigate compliance risk and accelerate adoption.

Corporate strategies and competitive plays from ingredient innovators, contract manufacturers, and commercial partners that are shaping the Urolithin B ecosystem

Companies active in the Urolithin B value chain are pursuing a range of strategic plays to secure competitive advantage, from proprietary fermentation platforms to partnerships that bundle clinical data with distribution strength. Innovators are investing in upstream process development to reduce variation and to support differentiation through consistent impurity profiles and enhanced stability. Contract manufacturers and ingredient houses are responding by expanding analytic capabilities, offering certified batches at multiple grades to satisfy cosmetic, food, and pharmaceutical specifications.

On the commercialization side, firms are prioritizing clinical validation and IP protection. Clinical programs focused on muscle function, mitochondrial biomarkers, and systemic anti-inflammatory endpoints help position ingredients for premium placement in supplements and for supportive claims in cosmetic formulations. Simultaneously, companies are using licensing arrangements and co-development partnerships with cosmetic manufacturers, dietary supplement manufacturers, and pharmaceutical companies to accelerate product launches and to de-risk market access. Strategic M&A activity and selective vertical integration are other recurring themes as firms seek to lock in supply, ensure quality, and capture greater share of downstream margin.

Finally, nimble players are leveraging distribution sophistication-combining direct sales relationships with online specialty retail strategies-to test consumer messaging, collect real-world evidence, and iterate formulations quickly. This blended approach allows commercial leaders to refine positioning in a data-driven manner while protecting premium channel relationships that require longer lead times and stronger technical support.

Practical, prioritized actions for manufacturers, formulators, and commercial teams to secure supply resilience, regulatory clearance, and market differentiation for Urolithin B

Industry leaders should adopt a multi-pronged, risk-managed strategy to capture value in the Urolithin B opportunity. First, prioritize investments in quality and provenance by expanding analytical infrastructure and by qualifying both biofermented and synthetic supply streams to ensure business continuity and to enable grade-specific deployments. This approach reduces dependence on single-source suppliers and supports rapid shifts between cosmetic grade, food grade, pharmaceutical grade, and standard grade as customer needs evolve.

Second, accelerate clinical and translational research aligned to target applications. Sponsors should focus on indication-relevant endpoints that resonate with cosmetic manufacturers, dietary supplement manufacturers, and pharmaceutical companies, thereby creating evidence packages that support differentiated claims and premium positioning. Early engagement with regulatory stakeholders and third-party certifiers will further streamline market entry and reduce time-to-shelf.

Third, diversify go-to-market channels by pairing traditional direct sales and specialty store strategies with targeted online launches. This combination enables rapid consumer testing and feedback while preserving institutional relationships that require deeper technical dialogue. Additionally, pursue strategic partnerships and licensing agreements that bundle clinical data with co-development commitments to de-risk commercialization and accelerate revenue generation.

Finally, develop regional playbooks that reflect local regulatory nuances, consumer preferences, and manufacturing capacities. Allocate capital toward manufacturing localization where tariffs or logistics impose persistent cost penalties, and invest in local R&D collaborations to tailor formulations for specific markets. Taken together, these actions position companies to convert scientific promise into sustainable commercial advantage.

A transparent, multi-method research approach combining primary interviews, laboratory verification, regulatory analysis, and supply chain mapping to underpin strategic recommendations

The research behind these insights integrates multiple complementary methods to ensure robustness and relevance. Primary inputs included structured interviews with ingredient developers, contract manufacturers, regulatory consultants, and formulators to capture operational realities and commercial intent. Secondary inputs involved a systematic review of peer-reviewed literature, clinical trial registries, patent filings, and regulatory notices to validate mechanisms of action, safety profiles, and dossier expectations. Together, these sources provided a layered understanding of scientific validation, intellectual property dynamics, and compliance standards.

Analytical verification was conducted using standardized laboratory profiling to confirm identity, assay, and impurity characterization across representative batches from both biofermented and synthetic sources. Supply chain mapping exercises traced raw material dependencies, production bottlenecks, and logistics constraints to identify points of fragility, while scenario modeling evaluated the operational implications of tariff changes and sourcing disruptions. Finally, a cross-sectional segmentation analysis aligned product forms and grades with end-user requirements to surface practical commercialization pathways.

This blended methodology-combining qualitative stakeholder input, quantitative laboratory verification, and strategic supply chain analysis-ensures that recommendations are grounded in both empirical evidence and real-world commercial dynamics. Transparency in methods and reproducibility of key tests were prioritized to allow clients to validate findings and to apply the insights to their specific decision frameworks.

A decisive synthesis of the scientific, manufacturing, and commercial imperatives that will determine which organizations successfully scale Urolithin B solutions

Urolithin B stands at a pivotal juncture where scientific validation, manufacturing maturity, and commercial demand intersect to create diverse pathways for value creation. The ingredient's trajectory will be shaped by the ability of stakeholders to demonstrate reproducible biological effects, to secure resilient and graded supply chains, and to align product form and claims with channel-specific expectations. As the evidence base grows and manufacturing options proliferate, companies that balance clinical investment with operational rigor and regional market sensitivity will be best positioned to translate potential into sustained commercial success.

In conclusion, the opportunity for Urolithin B extends beyond single-market launches: it requires an orchestrated strategy that integrates grade selection, source diversification, regulatory preparation, and channel-specific commercialization. Decision-makers should treat this moment as an inflection point to solidify partnerships, invest in quality systems, and accelerate targeted evidence generation. By doing so, organizations can minimize risk, capture premium positioning, and scale responsibly as the ingredient moves toward broader adoption across cosmetics, supplements, functional foods, and pharmaceutical applications.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urolithin B Market, by Application

  • 8.1. Cosmetics & Personal Care
  • 8.2. Dietary Supplements
  • 8.3. Functional Foods & Beverages
  • 8.4. Pharmaceuticals

9. Urolithin B Market, by Form

  • 9.1. Capsule
  • 9.2. Liquid
  • 9.3. Powder
  • 9.4. Tablet

10. Urolithin B Market, by Source

  • 10.1. Biofermented
  • 10.2. Synthetic

11. Urolithin B Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Online
  • 11.3. Specialty Stores

12. Urolithin B Market, by End User

  • 12.1. Cosmetic Manufacturers
  • 12.2. Dietary Supplement Manufacturers
  • 12.3. Pharmaceutical Companies
  • 12.4. Research Institutions

13. Urolithin B Market, by Grade

  • 13.1. Cosmetic Grade
  • 13.2. Food Grade
  • 13.3. Pharmaceutical Grade
  • 13.4. Standard Grade

14. Urolithin B Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Urolithin B Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Urolithin B Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Urolithin B Market

18. China Urolithin B Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bio-Botanica Inc.
  • 19.6. Cayman Chemical Company
  • 19.7. Hangzhou Ark Biotechnology Co., Ltd.
  • 19.8. Indena S.p.A.
  • 19.9. International Flavors & Fragrances Inc.
  • 19.10. Merck KGaA
  • 19.11. Nutraveris SAS
  • 19.12. PLT Health Solutions Ltd.
  • 19.13. Sabinsa Corporation
  • 19.14. Toronto Research Chemicals Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UROLITHIN B MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UROLITHIN B MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UROLITHIN B MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UROLITHIN B MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UROLITHIN B MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UROLITHIN B MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UROLITHIN B MARKET SIZE, BY GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UROLITHIN B MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL UROLITHIN B MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UROLITHIN B MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETICS & PERSONAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UROLITHIN B MARKET SIZE, BY FUNCTIONAL FOODS & BEVERAGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UROLITHIN B MARKET SIZE, BY FUNCTIONAL FOODS & BEVERAGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UROLITHIN B MARKET SIZE, BY FUNCTIONAL FOODS & BEVERAGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UROLITHIN B MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UROLITHIN B MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UROLITHIN B MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UROLITHIN B MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UROLITHIN B MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UROLITHIN B MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UROLITHIN B MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UROLITHIN B MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UROLITHIN B MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UROLITHIN B MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UROLITHIN B MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UROLITHIN B MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UROLITHIN B MARKET SIZE, BY BIOFERMENTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UROLITHIN B MARKET SIZE, BY BIOFERMENTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UROLITHIN B MARKET SIZE, BY BIOFERMENTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UROLITHIN B MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UROLITHIN B MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UROLITHIN B MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UROLITHIN B MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UROLITHIN B MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UROLITHIN B MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UROLITHIN B MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UROLITHIN B MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UROLITHIN B MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UROLITHIN B MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UROLITHIN B MARKET SIZE, BY SPECIALTY STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UROLITHIN B MARKET SIZE, BY SPECIALTY STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENT MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENT MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UROLITHIN B MARKET SIZE, BY DIETARY SUPPLEMENT MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UROLITHIN B MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UROLITHIN B MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UROLITHIN B MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL UROLITHIN B MARKET SIZE, BY COSMETIC GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL UROLITHIN B MARKET SIZE, BY FOOD GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UROLITHIN B MARKET SIZE, BY FOOD GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UROLITHIN B MARKET SIZE, BY FOOD GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UROLITHIN B MARKET SIZE, BY PHARMACEUTICAL GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL UROLITHIN B MARKET SIZE, BY STANDARD GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL UROLITHIN B MARKET SIZE, BY STANDARD GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL UROLITHIN B MARKET SIZE, BY STANDARD GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL UROLITHIN B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS UROLITHIN B MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL UROLITHIN B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 139. GCC UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GCC UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. G7 UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 160. G7 UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. G7 UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 167. NATO UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL UROLITHIN B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA UROLITHIN B MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA UROLITHIN B MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA UROLITHIN B MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA UROLITHIN B MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA UROLITHIN B MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA UROLITHIN B MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA UROLITHIN B MARKET SIZE, BY GRADE, 2018-2032 (USD MILLION)